Table 1:
Patient characteristics
| Clinicopathological background | |
| Age at recurrence (years) | |
| Median | 74.5 |
| Range | 48–87 |
| Sex | |
| Male | 50 |
| Female | 26 |
| Performance status at recurrence | |
| 0 | 23 |
| 1 | 33 |
| 2 | 13 |
| 3 | 6 |
| 4 | 1 |
| Smoking status | |
| Non-smoker | 23 |
| Light smoker | 10 |
| Heavy smoker | 40 |
| Unknown | 3 |
| Smoking index (pack-years) | |
| Median | 31 |
| Range | 6.7–90 |
| Histology | |
| Adenocarcinoma | 53 |
| Squamous cell carcinoma | 15 |
| Large cell carcinoma | 3 |
| Adenosquamous carcinoma | 3 |
| Pleomorphic carcinoma | 2 |
| Pathological stage | |
| IA/IB | 14/14 |
| IIA/IIB | 6/11 |
| IIIA/IIIB | 30/1 |
| Epidermal growth factor receptor mutation status | |
| Mutation | 28 |
| Wild-type | 39 |
| Unknown | 9 |
| Initial treatment | |
| Surgical approach | |
| Thoracotomy | 43 |
| Video-assisted thoracoscopic surgery | 33 |
| Surgical procedures | |
| Pneumonectomy | 0 |
| Lobectomy | 60 |
| Segmentectomy | 6 |
| Wedge resection | 10 |
| Lymph nodes dissection | |
| Systematic lymph node dissection | 56 |
| Mediastinal lymph node sampling | 11 |
| Hilar lymph node sampling | 10 |
| Induction chemotherapy | |
| No | 71 |
| Yes | 5 |
| Adjuvant chemotherapy | |
| No | 41 |
| Yes | 35 |
| Platinum-based | 19 |
| Uracil-tegafur | 16 |
| p-Stage IA | |
| Yes (%) | 4 (28) |
| p-Stage IB | |
| Yes (%) | 10 (71) |
| p-Stage II | |
| Yes (%) | 8 (47) |
| p-Stage III | |
| Yes (%) | 13 (42) |
| Recurrent disease | |
| Symptoms at recurrence | |
| Yes | 25 |
| No | 51 |
| Disease-free survival (months) | |
| Median | 12.8 |
| Range | 0.9–66.1 |
| Recurrent site | |
| Local (intrathoracic) | 42 |
| Distant (extrathoracic) | 16 |
| Both | 18 |
| No. of recurrent foci | |
| Single | 29 |
| Multiple | 47 |
| Therapy for recurrence | |
| Systemic chemotherapy | 64 |
| Palliative care | 12 |
| No. of chemotherapeutic regimen | |
| Median | 2 |
| Range | 1–7 |
| First-line therapeutic response | |
| Complete response | 4 |
| Partial response | 23 |
| Stable disease | 8 |
| Progressive disease | 21 |
| Not evaluable | 8a |
| EGFR-TKIs for recurrence | |
| Yes | 36 |
| No | 40 |
TKIs: tyrosine kinase inhibitors.
an = 6, non-measurable recurrent lesion on the RECIST guideline; n = 2, early discontinuation of chemotherapy due to adverse events.